{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:05:51Z","timestamp":1792271151258,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/nrrheum.2018.41","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T10:11:04Z","timestamp":1523527864000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":283,"title":["Classification of myositis"],"prefix":"10.1038","volume":"14","author":[{"given":"Ingrid E.","family":"Lundberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"BFnrrheum201841_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"M Dalakas","year":"2003","unstructured":"Dalakas, M. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971\u2013982 (2003).","journal-title":"Lancet"},{"key":"BFnrrheum201841_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrrheum201841_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","volume":"24","author":"R Euwer","year":"1991","unstructured":"Euwer, R. & Sontheimer, R. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J. Am. Acad. Dermatol. 24, 959 (1991).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201841_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360\u2013374 (1991).","journal-title":"Medicine"},{"key":"BFnrrheum201841_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/joim.12524","volume":"280","author":"IE Lundberg","year":"2016","unstructured":"Lundberg, I. E., Miller, F. W., Tj\u00e4rnlund, A. & Bottai, M. Diagnosis and classification of idiopathic inflammatory myopathies. J. Intern. Med. 280, 39\u201351 (2016).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201841_CR6","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 76, 1955\u20131964 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201841_CR7","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg, I. E. et al. 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 69, 2271\u20132282 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201841_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0002-9343(70)80006-7","volume":"48","author":"TA Medsger Jr","year":"1970","unstructured":"Medsger, T. A. Jr, Dawson, W. N. Jr & Masi, A. T. The epidemiology of polymyositis. Am. J. Med. 48, 715\u2013723 (1970).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201841_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/brain\/98.4.637","volume":"98","author":"R DeVere","year":"1975","unstructured":"DeVere, R. & Bradley, W. G. Polymyositis: its presentation, morbidity and mortality. Brain 98, 637\u2013666 (1975).","journal-title":"Brain"},{"key":"BFnrrheum201841_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201841_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403\u2013407 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201841_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A Bohan","year":"1977","unstructured":"Bohan, A. & Peter, J. B. Bowman, R. L. & Pearson, C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56, 255\u2013286 (1977).","journal-title":"Medicine"},{"key":"BFnrrheum201841_CR13","first-page":"668","volume":"22","author":"K Tanimoto","year":"1995","unstructured":"Tanimoto, K. et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 22, 668\u2013674 (1995).","journal-title":"J Rheumatol."},{"key":"BFnrrheum201841_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","volume":"9","author":"IN Targoff","year":"1997","unstructured":"Targoff, I. N. et al. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9, 527\u2013535 (1997).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201841_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov, Y. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84, 231\u2013249 (2005).","journal-title":"Medicine"},{"key":"BFnrrheum201841_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia, S., Oddis, C. V., Sato, S., Kuwana, M. & Aggarwal, R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J. Rheumatol. 44, 319\u2013325 (2017).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201841_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","volume":"46","author":"E Trallero-Aragu\u00e1s","year":"2016","unstructured":"Trallero-Aragu\u00e1s, E. et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin. Arthritis Rheum. 46, 225\u2013231 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201841_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge, Z. & McHugh, N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Intern. Med. 280, 8\u201323 (2016).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201841_CR19","doi-asserted-by":"publisher","unstructured":"McHugh, N.J. & Tansley, S.L. Autoantibodies in myositis Nat. Rev. Rheumatol. \n                    https:\/\/doi.org\/10.1038\/nrrheum.2018.56\n                    \n                   (2018).","DOI":"10.1038\/nrrheum.2018.56"},{"key":"BFnrrheum201841_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11926-014-0477-9","volume":"16","author":"PM Machado","year":"2014","unstructured":"Machado, P. M. et al. Ongoing developments in sporadic inclusion body myositis. Curr. Rheumatol. Rep. 16, 477 (2014).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum201841_CR21","first-page":"742","volume-title":"Arthritis (and Allied Conditions)","author":"CM Pearson","year":"1979","unstructured":"Pearson, C. M. in Arthritis (and Allied Conditions) (ed. McCarty, D. J.) 742\u2013761 (Lea & Febiger, Philadelphia, 1979)."},{"key":"BFnrrheum201841_CR22","doi-asserted-by":"publisher","first-page":"124S","DOI":"10.1038\/jid.1993.35","volume":"100","author":"R Euwer","year":"1993","unstructured":"Euwer, R. & Sontheimer, R. D. Amyopathic dermatomyositis: a review. J. Invest. Dermatol. 100, 124S\u2013127S (1993)","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum201841_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami, P., Schope, J. M., McDonald, L., Walling, H. W. & Sontheimer, R. D. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J. Am. Acad. Dermatol. 54, 597\u2013613 (2006)..","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl. 2","key":"BFnrrheum201841_CR24","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1067\/mjd.2003.126","volume":"48","author":"SH Hsiung","year":"2003","unstructured":"Hsiung, S. H. et al. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. J. Am. Acad. Dermatol. 48 (Suppl. 2). S11\u2013S14 (2003).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201841_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi, Y. et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch. Dermatol. 147, 391\u2013398 (2011).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum201841_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2012","unstructured":"Fiorentino, D., Chung, L., Zwerner, J., Roen, A. & Casciola-Rosen, L. The mucocutaneous and systemic phenotype in dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 65, 25\u201334 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201841_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","volume":"51","author":"Y Muro","year":"2016","unstructured":"Muro, Y. et al. Cutaneous manifestations in dermatomyositis: key clinical and serological features \u2014 a comprehensive review. Clin. Rev. Allergy Immunol. 51, 293\u2013302 (2016).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrrheum201841_CR28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae, H. et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136, 1341\u20131347 (2009).","journal-title":"Chest"},{"key":"BFnrrheum201841_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.14801","volume":"176","author":"CC Ang","year":"2017","unstructured":"Ang, C. C. et al. Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis. Br. J. Dermatol. 176, 231\u2013233 (2017).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino, D. F. et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449\u2013455 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201841_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/art.33402","volume":"64","author":"D Fiorentino","year":"2012","unstructured":"Fiorentino, D. & Casciola-Rosen, L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 64, 346\u2013349 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201841_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers, A., Chung, L., Li. S., Casciola-Rosen, L. & Fiorentino, D. F. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909\u20131914 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201841_CR33","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","volume":"28","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto, M., Watanabe, R., Ishitsuka, Y. & Okiyama, N. Recent advances in dermatomyositis-specific autoantibodies. Curr. Opin. Rheumatol. 28, 636\u2013644 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201841_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","volume":"159","author":"RQ Klein","year":"2008","unstructured":"Klein, R. Q. et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br. J. Dermatol. 159, 887\u2013894 (2008).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.13915","volume":"173","author":"CO Anyanwu","year":"2015","unstructured":"Anyanwu, C. O. et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br. J. Dermatol. 173, 969\u2013974 (2015).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/bjd.15596","volume":"177","author":"J Tiao","year":"2017","unstructured":"Tiao, J. et al. Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 177, 1086\u20131092 (2017).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjd.15140","volume":"176","author":"J Tiao","year":"2017","unstructured":"Tiao, J. et al. The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists. Br. J. Dermatol. 176, 423\u2013430 (2017).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/bjd.13167","volume":"172","author":"ES Robinson","year":"2015","unstructured":"Robinson, E. S., Feng, R., Okawa, J. & Werth, V. P. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br. J. Dermatol. 172, 169\u2013174 (2015).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","volume":"162","author":"M Yassaee","year":"2010","unstructured":"Yassaee, M., et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br. J. Dermatol. 162, 669\u2013673 (2010).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201841_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/jid.2011.440","volume":"132","author":"R Goreshi","year":"2012","unstructured":"Goreshi, R. et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J. Invest. Dermatol. 132, 1117\u20131124 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum201841_CR41","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard, C. et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br. J. Dermatol. 176, 1224\u20131230 (2017).","journal-title":"Br. J. Dermatol."},{"issue":"Suppl.","key":"BFnrrheum201841_CR42","first-page":"7L","volume":"69","author":"VP Werth","year":"2017","unstructured":"Werth, V. P. et al. A phase 2 study of safety and efficacy o anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis [abstract]. Arthritis Rheum. 69 (Suppl.), 7L (2017).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201841_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ana.410160207","volume":"16","author":"AG Engel","year":"1984","unstructured":"Engel, A. G. &Arahata, K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann. Neurol. 16, 209\u2013215 (1984).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201841_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.410270402","volume":"27","author":"AM Emslie-Smith","year":"1990","unstructured":"Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343\u2013356 (1990).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201841_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs, R. C., et al. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705\u2013713 (1995).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201841_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","volume":"12","author":"MF Van der Meulen","year":"2003","unstructured":"Van der Meulen, M. F. et al. Polymyositis: an overdiagnosed entity. Neurology 12, 316\u2013321 (2003).","journal-title":"Neurology"},{"key":"BFnrrheum201841_CR47","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","volume":"84","author":"S Brady","year":"2013","unstructured":"Brady, S., Squier, W. & Hilton-Jones, D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J. Neurol. Neurosurg. Psychiatr. 84, 1240\u20131246 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"BFnrrheum201841_CR48","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose, M. R. & ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2\u20134 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044\u20131055 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrrheum201841_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"29","author":"TE Lloyd","year":"2014","unstructured":"Lloyd, T. E. et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 29, 426\u2013433 (2014).","journal-title":"Neurology"},{"key":"BFnrrheum201841_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","volume":"38","author":"W Stenzel","year":"2012","unstructured":"Stenzel, W., Goebel, H. H. & Aronica, E. Review: immunemediated necrotizing myopathies\u2013 a heterogeneous group of diseases with specific myopathological features. Appl. Neurobiol. Neuropathol. 38, 632\u2013646 (2012).","journal-title":"Appl. Neurobiol. Neuropathol."},{"key":"BFnrrheum201841_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach, Y. et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul. Disord. 28, 87\u201399 (2018).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrrheum201841_CR52","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","volume":"261","author":"J Van de Vlekkert","year":"2014","unstructured":"Van de Vlekkert, J., Hoogendijk, J. E. & de Visser, M. Long-term follow-up of 62 patients with myositis. J. Neurol. 261, 992\u2013998 (2014).","journal-title":"J. Neurol."},{"key":"BFnrrheum201841_CR53","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3899\/jrheum.141443","volume":"42","author":"I Pinal-Fernandez","year":"2015","unstructured":"Pinal-Fernandez, I., Casciola-Rosen, L. A., Christopher-Stine, L., Corse, A. M. & Mammen, A. L. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J. Rheumatol. 42, 1448\u20131454 (2015).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201841_CR54","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nan.12380","volume":"43","author":"Y Allenbach","year":"2017","unstructured":"Allenbach, Y., Benveniste, O., Goebel, H.-H. & Stenzel, W. Integrated classification of inflammatory myopathies. Neuropathol. Appl. Neurobiol. 43, 62\u201381 (2017).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"BFnrrheum201841_CR55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","volume":"74","author":"E Noguchi","year":"2017","unstructured":"Noguchi, E. et al. Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol. 74, 992\u2013999 (2017).","journal-title":"JAMA Neurol."},{"key":"BFnrrheum201841_CR56","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/jnnp.68.4.472","volume":"68","author":"T Mozaffar","year":"2000","unstructured":"Mozaffar, T. & Pestronk, A. Myopathy with anti-Jo-1 antibodies: Pathology in perimysium and neighbouring muscle fibres. J. Neurol. Neurosurg. Psychiatry, 68, 472\u2013478 (2000).","journal-title":"J. Neurol. Neurosurg. Psychiatry,"},{"key":"BFnrrheum201841_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","volume":"23","author":"J Aouizerate","year":"2014","unstructured":"Aouizerate, J. et al. Myofiber HLA-DR espression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol. Commun. 23, 154 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"BFnrrheum201841_CR58","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/brain\/awv192","volume":"138","author":"L Mescam-Mancini","year":"2015","unstructured":"Mescam-Mancini, L. et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138, 2485\u20132492 (2015).","journal-title":"Brain"},{"key":"BFnrrheum201841_CR59","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","volume":"84","author":"W Stenzel","year":"2015","unstructured":"Stenzel, W. et al. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome\u2013induced dysimmune myopathy. Neurology 84, 1346\u20131354 (2015).","journal-title":"Neurology"},{"key":"BFnrrheum201841_CR60","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1093\/brain\/aww125","volume":"139","author":"A Uruha","year":"2016","unstructured":"Uruha, A., Suzuki, S., Suzuki, N. & Nishino, I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain 139, e50 (2016).","journal-title":"Brain"},{"key":"BFnrrheum201841_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/BOR.0000000000000335","volume":"28","author":"I Pinal-Fernandez","year":"2016","unstructured":"Pinal-Fernandez, I. & Mammen, A. L. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr. Opin. Rheumatol. 28, 619\u2013624 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201841_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","volume":"94","author":"M De Visser","year":"1989","unstructured":"De Visser, M., Emslie-Smith, A. M. & Engel, A. G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J. Neurol. Sci. 94, 181\u2013192 (1989).","journal-title":"J. Neurol. Sci."},{"key":"BFnrrheum201841_CR63","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/art.23012","volume":"57","author":"LR Wedderburn","year":"2007","unstructured":"Wedderburn, L. R. et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 57, 1192\u20131201 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201841_CR64","doi-asserted-by":"publisher","unstructured":"Patel, B. Neelam, K. & Werth, V. P. Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease. J. Am. Acad. Dermatol. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2017.12.055\n                    \n                   (2017).","DOI":"10.1016\/j.jaad.2017.12.055"},{"key":"BFnrrheum201841_CR65","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487\u20131498 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201841_CR66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","volume":"23","author":"A Pestronk","year":"2011","unstructured":"Pestronk, A. Acquired immune and inflammatory myopathies: pathologic classification. Curr. Opin. Rheumatol. 23, 595\u2013604 (2011).","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.41","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2018.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:43:05Z","timestamp":1684456985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2018.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFnrrheum201841"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2018.41","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733039469.793567609","asserted-by":"object"}]},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"12 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}